Captrust Financial Advisors Ascendis Pharma A/S Transaction History

Captrust Financial Advisors

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$86.1 - $127.36 $346,294 - $512,241	4,022 Added 16.74%	28,051 $3.53 Million
Q3 2023 Nov 14, 2023	BUY	$86.5 - $103.97 $1.01 Million - $1.22 Million	11,708 Added 95.02%	24,029 $2.25 Million
Q2 2023 Aug 14, 2023	SELL	$69.96 - $97.84 $279 - $391	-4 Reduced 0.03%	12,321 $1.1 Million
Q4 2022 Feb 15, 2023	BUY	$99.42 - $131.97 $1.23 Million - $1.63 Million	12,325 New	12,325 $1.51 Million
Q2 2022 Aug 23, 2022	SELL	$78.08 - $117.61 $1,717 - $2,587	-22 Reduced 1.36%	1,594 $148,000
Q2 2022 Aug 16, 2022	BUY	$78.08 - $117.61 $44,505 - $67,037	570 Added 54.49%	1,616 $150,000
Q1 2022 May 16, 2022	BUY	$102.18 - $135.75 $103,508 - $137,514	1,013 Added 3069.7%	1,046 $123,000
Q3 2020 Nov 17, 2020	BUY	$134.29 - $154.32 $4,028 - $4,629	30 Added 1000.0%	33 $5,000
Q2 2020 Aug 14, 2020	BUY	$110.87 - $156.01 $332 - $468	3 New	3 $0

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.